Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables: 2010-2025

Historic Receivables for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Sep 2025 value amounting to $6.8 million.

  • Arrowhead Pharmaceuticals' Receivables was N/A to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year change of. This contributed to the annual value of $6.8 million for FY2025, which is N/A change from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Receivables stood at $6.8 million for FY2025, which was up 9.89% from $6.2 million recorded in FY2022.
  • Arrowhead Pharmaceuticals' 5-year Receivables high stood at $20.3 million for FY2021, and its period low was $6.2 million during FY2022.
  • Over the past 1 years, Arrowhead Pharmaceuticals' median Receivables value was $6.8 million (recorded in 2025), while the average stood at $6.8 million.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 1,130.56% in 2021, then slumped by 69.34% in 2022.
  • Arrowhead Pharmaceuticals' Receivables (Yearly) stood at $20.3 million in 2021, then slumped by 69.34% to $6.2 million in 2022, then reached $6.8 million in 2025.